Clinical Trial Update: Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of Onartuzumab and/or Bevacizumab in combination with Paclitaxel for metastatic triple-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Onartuzumab (onartuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED